Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025)

Neumora Therapeutics (NMRA) posted quarterly Other Operating Expenses of $5.0 million for Q3 2025, down 92.18% quarter-over-quarter from $63.9 million in Q4 2023.

Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025) Analysis & Trends

Neumora Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2025.

  • In Q3 2025, Other Operating Expenses changed N/A year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, changed N/A from the prior year.
  • Other Operating Expenses for Q3 2025 stood at $5.0 million, down from $63.9 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $63.9 million in Q4 2023, with the low at $5.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Neumora Therapeutics 296.45 Mn 296.45 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 5.00 Mn
Dec 31, 2023 63.90 Mn